Validation to Brazilian Portuguese version of the Self-Care Inventory-revised for adults with type 2 diabetes

Gabriela H. Telô1,2
https://orcid.org/0000-0001-9093-383X
Fernando de Quadros Iorra2
https://orcid.org/0000-0002-6503-9323
Bruno S. Velho2
https://orcid.org/0000-0002-8401-1019
Karen Sparrenberger2
https://orcid.org/0000-0002-3444-9178
Beatriz D. Schaan2,3
https://orcid.org/0000-0002-2128-8387

ABSTRACT

Objective: The aim of this study was to cross-culturally adapt and validate the Brazilian Portuguese version of SCI-R to adults with type 2 diabetes.

Materials and methods: The SCI-R is a 15-question survey that reflects how well patients with diabetes have adhered to treatment recommendations. A pretest (n = 40) was first performed to improve comprehension of the survey items. A final version was then self-administered in another 75 adults with type 2 diabetes to determine the survey's reliability and validity according to its association with HbA1c. Finally, we conducted a test-retest reliability analysis over three weeks to stabilize the sample and determine intra-observer variability.

Results: After the pretest phase, the final sample's (N = 75) mean age was 59.9 ± 7.5 years and mean HbA1c level was 8.6 ± 1.5% (70 ± 16.4 mmol/mol). The initial Cronbach's alpha was 0.61; however, further analysis showed that four items had low item correlation and were excluded from the final version, which increased the Cronbach's alpha to 0.63. In predictive validity analysis, HbA1c levels correlated significantly with total survey scores (r = -0.38, P = 0.001). The intra-class correlation coefficient between baseline and three-week scores was 0.93, which indicates high reproducibility.

Conclusions: The Brazilian Portuguese version of the SCI-R is a valid tool for measuring treatment adherence in adults with type 2 diabetes.

Keywords: Validation; survey; adherence; type 2 diabetes

INTRODUCTION

It is estimated that diabetes affects 14.3 million adults in Brazil, which represents 10.2% of the Brazilian population aged 20-79 years (1), ranking high among the health problems in this country (2). Despite all the evidence that glycemic control can be optimized and microvascular and macrovascular complications can be prevented (3,4), adherence to diabetes treatment has still been a challenge (5). In Brazil, most type 2 diabetes patients present poor glycemic control, which is strongly associated with poor adherence to diabetes treatment (6). Among those treated in the public healthcare system, the hemoglobin A1c (HbA1c) levels of less than 30% were within the American Diabetes Association target (6,7).

There are several key elements in diabetes management, including self-care education about medication, physical activity, nutrition and blood glucose monitoring (7,8). Considering that improved treatment adherence could optimize glycemic control (5,9,10), instruments that assess patient compliance are essential. However, cultural barriers have limited the available tools for Brazilian adults with type 2 diabetes.

Diabetes-specific instruments have high acceptance among patients and allow evaluation of specific aspects of the disease. The number of cross-culturally adapted or validated questionnaires for Brazilian culture is still insufficient for the national demand. The Self-Care Inventory – Revised (SCI-R) is a brief, psychometrically sound measure of adherence to recommended diabetes self-care behaviors in adults with diabetes (11). This survey has been previously validated in Brazil in a population of adults with type 1 diabetes but not type 2 diabetes (12). Currently, no Brazilian Portuguese survey
Validation to Brazilian Portuguese of the Self-Care Inventory-revised

P.S. Campbell, et al.

Arch Endocrinol Metab. 2020;64/2

has been validated to evaluate treatment adherence in both type 1 and type 2 diabetes. The aim of this study was to cross-culturally adapt and validate the Brazilian Portuguese version of the SCI-R in adults with type 2 diabetes.

MATERIALS AND METHODS

Participants and setting

This study was carried out from January to December 2016 in a diabetes outpatient clinic of the Hospital de Clínicas de Porto Alegre, a tertiary university hospital in Southern Brazil. Patients were selected by searching the hospital’s medical record database, and those who met the eligibility criteria were contacted by telephone and provided with information about the study. Patients were eligible if they were aged 18 and older, had been previously diagnosed with type 2 diabetes and had Brazilian cultural identity. Exclusion criteria consisted of any communication or understanding barrier, such as mental disorder or illiteracy. Such barriers were identified based on self, family or medical reports. The local institutional review board approved this study protocol, and all participants provided written informed consent.

Instrument and procedures

The SCI-R is a self-administered 15-question survey that uses a 5-point Likert scale to reflect how well respondents have followed diabetes treatment recommendations over the previous 1-2 months (i.e., 1 = “never” to 5 = “always”). Higher scores indicate better adherence. In Brazil, this measure has been recently validated in adults with type 1 diabetes, showing acceptable internal reliability and correlation between glycemic control and total score (12).

Details of the transcultural adaptation of the original SCI-R have been described elsewhere (12), i.e. the translation, back-translation and revision strategies of the Portuguese version by a committee of specialists, including two endocrinologists and a linguistics specialist, among other researchers.

To enhance the instrument’s construct validity, the previously adapted version (12) was first applied to 40 patients (13) in a pretest to discover the respondents’ interpretation of each item. Based on this feedback, modifications were made in certain items to ensure easy comprehension. Upon the conclusion of the adaptation process, and based on a suggestion regarding validation sample size (13), another 75 patients were selected to answer the final version of SCI-R to determine the instrument’s reliability and validity according to association with HbA1c levels. Finally, we conducted a test-retest reliability analysis over three weeks in 25% of the sample (n = 20) to stabilize the sample and determine intra-observer variability.

Statistical analyses

Internal consistency was assessed by calculating Cronbach’s alpha for total score and item-total score correlations. Values > 0.6 were considered acceptable. The impact of removing each item on the Cronbach’s alpha value was then assessed, and a low item-correlation could lead to the exclusion of a particular question. Pearson’s correlation coefficient was used to determine the predictive validity between total SCI-R scores and HbA1c levels. Intra-class correlation was used to evaluate intra-observer variability. The sample size was based on recommendations in the literature for survey validation studies (13).

RESULTS

A total of 242 patients were enrolled in this study. Of these, 54 declined to participate, six were excluded due to cognitive or language impairment and 67 did not have a valid telephone contact or did not answer calls. The first 40 patients included were selected for the pretest phase, i.e. completing the survey and indicating comprehension difficulties in each question. This led to modifications in five items to facilitate comprehension (see supplementary Table 1). The main strategy in this process was adding parenthetical statements after nouns to provide additional information. For example, in item one, “finger glucose meter device” was added to the item “verify blood glucose level with a monitor”. After
this step, the next 75 patients included were considered the final sample and completed the adjusted version of the survey. We found no significant differences in age, sex or diabetes duration between participants and decliners, or between the pretest and final samples.

Overall (N = 75), the mean age was 59.9 ± 7.5 years; 59% were women and 71% were Caucasian. The mean diabetes duration was 16.5 ± 8.6 years, and the mean HbA1c level was 8.7 ± 1.5% (72 ± 16.4 mmol/mol) (see Table 1). The SCI-R survey was self-administered and completed within 8-10 minutes. The initial Cronbach’s alpha was 0.61. The analysis showed that four items (checking ketones, modifying the medication dose, eating only the recommended amount of carbohydrates while hypoglycemic, and wearing a medical alert) had low-item correlation and were excluded from the final SCI-R version, which increased the Cronbach’s alpha to 0.63. In predictive validity analysis, HbA1c levels correlated significantly with total survey scores (r = -0.38, P = 0.001). Test-retest reliability was analyzed over three weeks using data from 25% of the sample (n = 20). The intra-class correlation coefficient between baseline and three-week scores was 0.93, which indicates high reproducibility.

**Table 1.** Participant demographics and clinical characteristics

| Characteristics | Mean ± SD or %          |
|-----------------|-------------------------|
| Age (years)     | 59.9 ± 7.5              |
| Sex (% female)  | 59                      |
| Ethnicity (% Caucasian) | 71               |
| Educational level (years of study) | 7.6 ± 3.1 |
| Weight status   |                         |
| Normal (%)      | 9                       |
| Overweight (%)  | 23                      |
| Obese (%)       | 68                      |
| Age at diabetes diagnosis (years) | 43.3 ± 9.2         |
| Diabetes duration (years) | 16.5 ± 8.6         |
| HbA1c (%)       | 8.7 ± 1.5               |
| HbA1c (mmol/mol) | 72 ± 16.4              |
| Chronic diabetes complication (%) | 79                |
| Insulin use (%) | 80                      |

Data are mean ± standard deviation (SD) or %. HbA1c: hemoglobin A1c.

**DISCUSSION**

Due to the increasing number of diabetes cases in Brazil, it has become necessary to develop specific instruments to help health professionals with the follow-up of these patients. We conducted a complementary adjustment process of the SCI-R survey, which had been previously cross-culturally adapted to Brazilian Portuguese and validated for type 1 diabetes (12). In this study, we evaluated the reliability and validity of this survey in Brazilian adults with type 2 diabetes. To our knowledge, this is the first survey validated in Brazil for evaluating treatment adherence in both type 1 and type 2 diabetes populations. The questionnaire presented satisfactory psychometric properties and is thus an acceptable instrument for measuring treatment adherence in the studied population.

Cronbach’s alpha is used to establish internal consistency, and results higher than 0.6 are considered acceptable when evaluating measurement instruments. We found, as in other validations of this same survey (12,14), a lower Cronbach’s alpha than the original SCI-R study (α = 0.87) (11). This difference could be partially explained by the fact that the original questionnaire was applied in both type 1 and type 2 diabetes patients. Its strict use in type 2 diabetes patients in this study led to the loss of four questions that were mainly related to type 1 diabetes treatment and, as a result, the final version included only 11 items. Furthermore, although easy to use, the survey is self-applied, which increases the probability of operational mistakes, such as misinterpreting instructions.

In the United Kingdom validation of the SCI-R survey for adults with type 2 diabetes (14), the authors evaluated how many questions could be excluded from the original survey without losing reliability, concluding that at least 11 questions should be maintained. Similar to our findings, this confirms the importance of retaining most items when adapting instruments to ensure reliability, despite the possibility of making an instrument more tiresome and less attractive.

In conclusion, the Brazilian Portuguese version of the SCI-R is an acceptable instrument for assessing treatment adherence in Brazilian adults with type 2 diabetes. The main purpose of this easy-to-use resource is to provide a general view of the patients’ self-care behaviors, serving as an accessory in clinical practice and a research instrument for measuring and interpreting individual compliance.

Ethics approval and consent to participate: this study was approved (15-0554) by the Hospital de Clínicas de Porto Alegre Institutional Ethics Committee, which is certified by the Office of Human Research Protections as an institutional review board. All respondents signed an informed consent form prior to participation in any study procedure.
Funding: this study was supported by FIPE (Fundo de Incentivo ao Pesquisador from Hospital de Clínicas de Porto Alegre) and CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico).

Author contributions: G.H.T. and F.Q.I. researched and analyzed data and wrote the manuscript. B.S.V. and K.S. researched data and reviewed the manuscript. B.D.S. analyzed data and edited the manuscript. All authors have approved the final version of this manuscript.

Disclosure: no potential conflict of interest relevant to this article was reported.

REFERENCES
1. Telo GH, Cureau FV, de Souza MS, Andrade TS, Copes F, Schaan BD. Prevalence of diabetes in Brazil over time: a systematic review with meta-analysis. Diabetol Metab Syndr. 2016;8(1):65.
2. Costa AF, Flor LS, Campos MR, Oliveira AF, Costa MF, Silva RS, et al. Burden of type 2 diabetes mellitus in Brazil. Cad Saude Publica. 2017;33(2):e00197915.
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53.
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med. 2008;359(15):1577-89.
5. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999;48(5):643-8.
6. Viana LV, Leitao CB, Kramer OK, Zucatti AT, Jezini DL, Felicio J, et al. Poor glycaemic control in Brazilian patients with type 2 diabetes attending the public healthcare system: a cross-sectional study. BMJ Open. 2013;3(9):e003336.
7. Diabetes A. 4. Lifestyle Management. Diabetes Care. 2017;40(Supplement 1):S33-S43.
8. American Association of Diabetes E. Standards for outcomes measurement of diabetes self-management education. Diabetes Educ. 2003;29(5):804, 8-10, 13-6.
9. Gomes MB, Coral M, Cobas RA, Dib SA, Canani LH, Nery M, et al. Prevalence of adults with type 1 diabetes who meet the goals of care in daily clinical practice: a nationwide multicenter study in Brazil. Diabetes Res Clin Pract. 2012;97(1):63-70.
10. Gomes MB, Negrato CA. Adherence to insulin therapeutic regimens in patients with type 1 diabetes. A nationwide survey in Brazil. Diabetes Res Clin Pract. 2016;120:47-55.
11. Weinger K, Butler HA, Welch GW, La Greca AM. Measuring diabetes self-care: a psychometric analysis of the Self-Care Inventory-Revised with adults. Diabetes care. 2005;28(6):1346-52.
12. Telo GH, de Souza MS, Schaan BD. Cross-cultural adaptation and validation to Brazilian Portuguese of two measuring adherence instruments for patients with type 1 diabetes. Diabetol Metab Syndr. 2014;6:141.
13. Sapnas KG, Zeller RA. Minimizing sample size when using exploratory factor analysis for measurement. J Nurs Meas. 2002;10(2):135-54.
14. Khagram L, Martin CR, Davies MJ, Speight J. Psychometric validation of the Self-Care Inventory-Revised (SCI-R) in UK adults with type 2 diabetes using data from the ATLANTUS Follow-on study. Health Qual Life Outcomes. 2013;11:24.
Supplementary Table 1

**Original Version**

INVENTÁRIO DE AUTOCUIDADO – DIABETES (SCI-R)

Este questionário avalia o que você realmente faz, e não o que você é recomendado a fazer.

Para cada pergunta abaixo, como você tem seguido o seu tratamento do diabetes nos últimos 1 a 2 meses?

| Nunca | Raramente | Às vezes | Geralmente | Sempre |
|-------|-----------|----------|------------|--------|
| 1. Verifica a glicose no sangue com monitor | (1) | (2) | (3) | (4) | (5) |
| 2. Anota os resultados de glicose no sangue | (1) | (2) | (3) | (4) | (5) |
| 3. Verifica cetonas quando o nível de glicose está alto | (1) | (2) | (3) | (4) | (5) |
| 4. Usa a dose correta de insulina | (1) | (2) | (3) | (4) | (5) |
| 5. Usa a insulina na hora certa | (1) | (2) | (3) | (4) | (5) |
| 6. Come as porções corretas de comida | (1) | (2) | (3) | (4) | (5) |
| 7. Come as refeições e lanches na hora certa | (1) | (2) | (3) | (4) | (5) |
| 8. Anota o que come | (1) | (2) | (3) | (4) | (5) |
| 9. Lê os rótulos dos alimentos | (1) | (2) | (3) | (4) | (5) |
| 10. Trata a glicose baixa no sangue com somente a quantidade recomendada de carboidratos | (1) | (2) | (3) | (4) | (5) |
| 11. Carrega açúcar para, em caso de emergência, tratar a glicose baixa no sangue | (1) | (2) | (3) | (4) | (5) |
| 12. Comparece às consultas marcadas | (1) | (2) | (3) | (4) | (5) |
| 13. Faz exercícios | (1) | (2) | (3) | (4) | (5) |
| 14. Ajusta a dose de insulina baseado nos valores da glicose, comida e exercícios | (1) | (2) | (3) | (4) | (5) |

**Current Version**

INVENTÁRIO DE AUTOCUIDADO – DIABETES (SCI-R)

Este questionário avalia o que você realmente faz, e não o que você é recomendado a fazer.

Para cada pergunta abaixo, como você tem seguido o seu tratamento do diabetes nos últimos 1 a 2 meses?

| Nunca | Raramente | Às vezes | Geralmente | Sempre |
|-------|-----------|----------|------------|--------|
| 1. Verifica a glicose no sangue com monitor (aparelho de medir glicose no dedo) | (1) | (2) | (3) | (4) | (5) |
| 2. Anota os resultados de glicose no sangue quando verifica com o monitor | (1) | (2) | (3) | (4) | (5) |
| 3. Verifica cetonas no sangue ou na urina quando o nível de glicose está alto | (1) | (2) | (3) | (4) | (5) |
| 4. Usa a dose correta de insulina ou dos remédios para diabetes | (1) | (2) | (3) | (4) | (5) |
| 5. Usa a insulina ou os remédios para diabetes na hora certa | (1) | (2) | (3) | (4) | (5) |
| 6. Come as porções corretas de comida | (1) | (2) | (3) | (4) | (5) |
| 7. Come as refeições e lanches na hora certa | (1) | (2) | (3) | (4) | (5) |
| 8. Anota o que come | (1) | (2) | (3) | (4) | (5) |
| 9. Lê os rótulos dos alimentos | (1) | (2) | (3) | (4) | (5) |
| 10. Trata a glicose baixa no sangue com somente a quantidade recomendada de carboidratos | (1) | (2) | (3) | (4) | (5) |
| 11. Carrega açúcar para, em caso de emergência, tratar a glicose baixa no sangue | (1) | (2) | (3) | (4) | (5) |
| 12. Comparece às consultas marcadas | (1) | (2) | (3) | (4) | (5) |
| 13. Faz exercícios | (1) | (2) | (3) | (4) | (5) |
| 14. Ajusta a dose de insulina baseado nos valores da glicose, comida e exercícios | (1) | (2) | (3) | (4) | (5) |

| 11. Quando a glicose no sangue está baixa, trata somente com a quantidade de carboidratos recomendada | (1) | (2) | (3) | (4) | (5) |
| 12. Comparece às consultas marcadas | (1) | (2) | (3) | (4) | (5) |
| 13. Carrega algum tipo de identificação que comprove o diabetes (por exemplo: cartão, pulseira, colar) | (1) | (2) | (3) | (4) | (5) |
| 14. Faz exercícios | (1) | (2) | (3) | (4) | (5) |
| 15. Você modifica a dose de insulina baseado nos valores da glicose, comida e/ou exercícios | (1) | (2) | (3) | (4) | (5) |

| 11. Quando a glicose no sangue está baixa, trata somente com a quantidade de carboidratos recomendada | (1) | (2) | (3) | (4) | (5) |
| 12. Comparece às consultas marcadas | (1) | (2) | (3) | (4) | (5) |
| 13. Carrega algum tipo de identificação que comprove o diabetes (por exemplo: cartão, pulseira, colar) | (1) | (2) | (3) | (4) | (5) |
| 14. Faz exercícios | (1) | (2) | (3) | (4) | (5) |
| 15. Você modifica a dose de insulina baseado nos valores da glicose, comida e/ou exercícios | (1) | (2) | (3) | (4) | (5) |